UniQure (QURE) stock catapulted more than 200% Wednesday after the company said its experimental gene therapy successfully treated Huntington's disease. Huntington's disease is a neurological condition that slowly destroys brain cells, robbing patients of the ability to move and reason. But a high dose of UniQure's AMT-130 slowed disease progression by 75% after three years. Dr. Sarah Tabrizi, director of the University College London Huntington's Disease Center, called the results "groundbreaking." "These data are the most convincing in the field to date and underscore potential disease-modifying effects in Huntington's disease, where an urgent need persists," she said in a statement. "These data indicate that AMT-130 has the potential to meaningfully slow disease progression — offering long-awaited hope to individuals and families impacted by this devastating disease." UniQure stock launched 247.7% to 47.50. Shares touched a nearly five-year high. UniQure said patients who received the gene therapy showed a statistically significant improvement on the composite Unified Huntington's Disease Rating Scale, or cUHDRS. The scale was created to assess disease progression in early-to-moderate Huntington's disease.
Published: September 24, 2025 5:56 pm
Source: Investor's Business Daily — Read original